JNJ · Mega Cap · NYSE · Healthcare · Drug Manufacturers - General
Free research brief
Free to track. No card required.
Price, momentum, and the numbers behind the story.
Overall score
56/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Where the analysts and the crowd stand, and what it's worth to know first.
Lowest
$190
Current price
$272.45
Median target
$280
Highest
$305
What it earns and where it earns it, what you're paying for the stock, and the risk sitting on the balance sheet.
ROIC
Strong · Excellent capital returns
19.9%
ROE
Favorable · 26.4% - strong capital efficiency
25.7%
Debt / equity
Favorable · 0.68 - solid leverage
0.58x
JNJ against the names it's actually compared to.
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $651.25B | 31.3 | +8.1% | 56 | |
| $11.67B | 22.2 | +19.7% | 78 | |
| $4.35B | 13.1 | +13.5% | 77 | |
| $34.85B | 36.5 | +15.5% | 77 | |
| $1.18T | 42.7 | +49.6% | 76 |
Every story that touched the stock this week, newest first.